A Phase 2 interventional study of activated recombinant human factor VII and activated recombinant human factor VII in Acquired Bleeding Disorder and Cirrhosis, sponsored by Novo Nordisk A/S. Completed at 7 sites in 3 countries. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-13.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Fibrosis with a site in China — 44 open to participants now, 53 under way, 2 of them phase 3. Fibrosis · China.
Among the 128 studies in Fibrosis with a site in China, this one is the 20th largest by enrollment of the 67 interventional ones that give a count, is the only one that started in 2001, is one of 5 in phase 2, and was the 5th registered.
1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.
Browse Fibrosis studies →44 of the 128 studies in Fibrosis with a site in China are open now. Recruiting first, the newest first:
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Hudson Biotech · Sites in China
Ages 18–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 9 · Phase 3 8 · Phase 4 13
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 235 is above the median of 63 across 841 interventional studies indexed under Fibrosis.
Median enrollment 120 across the 67 interventional studies, 400 across the 61 observational. Of the 39 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 128 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 2 studies filed under Fibrosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Fibrosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06984497General Hospital of Shenyang Military RegionHuman Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD | 2026-12 |
| NCT07031843Juan KangExploration of a Novel Prognostic Prediction Model for Liver Cirrhosis | 2026-12-30 |
| NCT06981091Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis | 2027-01-08 |
| NCT07481734Hudson BiotechTesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | 2027-02-14 |
| NCT06858553Minhu ChenAI-Assisted MRE for Intestinal Fibrosis in Crohn's Disease | 2027-02-28 |
Add all 14 to your calendar (.ics) → With an account.
Among the 128 studies in Fibrosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: activated recombinant human factor VII
Drug: activated recombinant human factor VII
Drug: placebo
An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
An initial placebo bolus dose followed by placebo every second hour until completion of surgery
The RBC transfusion requirements
Number of transfusion product units
Change in coagulation-related parameters
Adverse events
The record gives a start of Jul 2001, a primary completion of Dec 2002 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa